U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Deal

Source: Reuters

A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a report in Reuters. 

The U.S. Court of Appeals for the Federal Circuit said a tribunal run by the U.S. Patent and Trademark Office has authority to review the validity of patents covering Allergan’s dry eye drug Restasis.

Read the full article.

Related Content